Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Messina, Italy.
AJR Am J Roentgenol. 2010 Dec;195(6):W394-9. doi: 10.2214/AJR.09.3721.
The purpose of this study was to evaluate cardiac MRI features in a group of patients with transthyretin familial amyloid polyneuropathy (FAP).
Sixteen patients with transthyretin FAP underwent 2D echocardiography with Doppler examination, cardiac MRI, and (99m)Tc-diphosphonate (DPD) scintigraphy. Four patients had peripheral polyneuropathy, three had carpal tunnel syndrome, one patient had symptoms and signs of heart failure, and eight patients had no symptoms but had a family history of FAP. At MRI, cardiac function parameters and delayed contrast enhancement findings were evaluated.
Six patients had cardiac radiotracer uptake at scintigraphy (FAP cardiac group), and 10 patients had no cardiac uptake (FAP noncardiac group). The FAP cardiac group included the four patients with peripheral neuropathy, one patient with carpal tunnel syndrome, and the only patient with heart failure. At MRI, abnormal contrast enhancement was found in all patients with positive scintigraphic findings and in no patient with negative scintigraphic findings. All patients had involvement of the left ventricle and other chambers or structures (atria, right ventricle, tricuspid valve leaflets). Left ventricular contrast enhancement was focal in four patients, subendocardial circumferential in one patient, and diffuse in one patient. The only patient with signs of heart failure had circumferential subendocardial enhancement.
Cardiac contrast-enhanced MRI can be used to identify cardiac amyloidosis in patients with FAP who do not have clinical signs of heart involvement. In these patients, the typical subendocardial circumferential pattern of contrast enhancement is rare. We observed unusual enhancement patterns as focal or diffuse left ventricular enhancement accompanied by enhancement of the atria, tricuspid valve, or right ventricle.
本研究旨在评估转甲状腺素蛋白家族性淀粉样多发性神经病(FAP)患者的心脏 MRI 特征。
16 例转甲状腺素蛋白 FAP 患者接受了二维超声心动图加多普勒检查、心脏 MRI 和(99m)Tc-二膦酸盐(DPD)闪烁扫描。4 例患者有周围神经病,3 例有腕管综合征,1 例有心力衰竭症状和体征,8 例患者无症状但有 FAP 家族史。在 MRI 上评估了心脏功能参数和延迟对比增强发现。
6 例患者闪烁扫描有心脏放射性示踪剂摄取(FAP 心脏组),10 例患者无心脏摄取(FAP 非心脏组)。FAP 心脏组包括 4 例周围神经病患者、1 例腕管综合征患者和唯一 1 例心力衰竭患者。在 MRI 上,所有有阳性闪烁扫描发现的患者均发现异常对比增强,而所有有阴性闪烁扫描发现的患者均无异常。所有患者均有左心室和其他腔室或结构(心房、右心室、三尖瓣叶)受累。4 例患者左心室对比增强呈局灶性,1 例呈心内膜下环状,1 例呈弥漫性。唯一有心力衰竭体征的患者有心内膜下环状增强。
心脏对比增强 MRI 可用于识别无心脏受累临床体征的 FAP 患者的心脏淀粉样变性。在这些患者中,典型的心内膜下环状对比增强模式很少见。我们观察到不常见的增强模式,如局灶性或弥漫性左心室增强,伴有心房、三尖瓣或右心室增强。